Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Buy" by Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) have been given a consensus recommendation of "Buy" by the ten ratings firms that are presently covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $40.38.

Several equities analysts have commented on ORKA shares. Wedbush reiterated an "outperform" rating and issued a $40.00 target price on shares of Oruka Therapeutics in a research report on Thursday, May 15th. Wall Street Zen upgraded Oruka Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday. Finally, BTIG Research started coverage on Oruka Therapeutics in a research report on Thursday, May 22nd. They issued a "buy" rating for the company.

Hedge Funds Weigh In On Oruka Therapeutics

Hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. bought a new stake in Oruka Therapeutics in the fourth quarter worth approximately $54,000. Squarepoint Ops LLC acquired a new stake in Oruka Therapeutics in the fourth quarter valued at approximately $236,000. Charles Schwab Investment Management Inc. acquired a new stake in Oruka Therapeutics in the fourth quarter valued at approximately $303,000. AlphaQuest LLC acquired a new stake in Oruka Therapeutics in the first quarter valued at approximately $168,000. Finally, Jane Street Group LLC acquired a new stake in Oruka Therapeutics in the fourth quarter valued at approximately $343,000. 56.44% of the stock is currently owned by institutional investors.

Oruka Therapeutics Price Performance

Shares of ORKA stock traded down $0.78 on Friday, hitting $10.90. 199,030 shares of the company's stock were exchanged, compared to its average volume of 220,255. Oruka Therapeutics has a 12 month low of $5.49 and a 12 month high of $31.13. The stock has a market cap of $408.10 million, a P/E ratio of -2.42 and a beta of -0.38. The company has a 50 day moving average of $10.76 and a 200 day moving average of $12.71.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.17. Sell-side analysts predict that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.